Related Experiment Video

Updated: Apr 4, 2026

An Inexpensive Adaptation of a Commercial Microwave Reactor for Solid Phase Peptide Synthesis
06:19

An Inexpensive Adaptation of a Commercial Microwave Reactor for Solid Phase Peptide Synthesis

Published on: November 22, 2024

961

Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?

Aaron S Kesselheim, Jonathan J Darrow

    Yale Journal of Health Policy, Law, and Ethics
    |September 4, 2015
    PubMed

    More Related Videos

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    1.7K
    Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery08:09

    Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery

    Published on: August 6, 2019

    6.3K

    Related Concept Videos

    Drug Regulation01:25

    Drug Regulation

    Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
    3.3K
    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    329
    Upstream Processing01:27

    Upstream Processing

    Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
    77
    Drug Products: Biologics, Biosimilars and Interchangeables01:28

    Drug Products: Biologics, Biosimilars and Interchangeables

    Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
    352
    Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

    Modified-Release Drug Delivery Systems: Rate-Programmed II

    Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
    91
    Bioequivalence studies: Biowaivers01:13

    Bioequivalence studies: Biowaivers

    In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
    393